| Overview |
| bs-22922R |
| c-fos Polyclonal Antibody |
| IHC-P, IHC-F, IF |
| Human |
| Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human c-fos |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 2353 |
| P01100 |
| Cytoplasm, Nucleus |
| Cellular oncogene fos; FBJ murine osteosarcoma viral v fos oncogene homolog antibody FBJ Osteosarcoma Virus; FOS; FOS protein; G0 G1 switch regulatory protein 7; G0S7; Oncogene FOS; Proto oncogene protein c fos; v fos FBJ murine osteosarcoma viral oncogene homolog; AP-1; p55; FOS_HUMAN; Proto-oncogene c-Fos; G0/G1 switch regulatory protein 7. |
| Nuclear phosphoprotein which forms a tight butnon-covalently linked complex with the JUN/AP-1 transcriptionfactor. In the heterodimer, FOS and JUN/AP-1 basic regions eachseems to interact with symmetrical DNA half sites. On TGF-betaactivation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at theAP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Hasa critical function in regulating the Has a critical function inregulating the development of cells destined to form and maintainthe skeleton. It is thought to have an important role in signaltransduction, cell proliferation and differentiation. |
| Application Dilution |
| IHC-P |
1:200-400 |
| IHC-F |
|
| IF |
|